Suchergebnisse - "Lenz, Oliver"

PubPharm (31)

1

A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection

enthalten in: Virology journal | 2018

von Zoulim, F. | Moreno, C. | Lee, S. | +9

2

Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation : The Phase II SATURN study

enthalten in: Transplant infectious disease : an official journal of the Transplantation Society | 2017

von Forns, X. | Berenguer, M. | Herzer, K. | +16

3

Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients : an open-label, rollover study

enthalten in: BMC infectious diseases | 2017

von Gane, E. | DeJesus, E. | Janczewska, E. | +15

4

Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response

enthalten in: PloS one | 2017

von Asselah, T. | Moreno, C. | Sarrazin, C. | +12

5

Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis : A phase 3 study (OPTIMIST-2)

enthalten in: Hepatology (Baltimore, Md.) | 2016

von Lawitz, E. | Matusow, G. | DeJesus, E. | +17

CommentIn: Hepatology. 2016 Aug;64(2):330-2. - PMID 26992027

6

Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis : OPTIMIST-1, a phase 3, randomized study

enthalten in: Hepatology (Baltimore, Md.) | 2016

von Kwo, P. | Gitlin, N. | Nahass, R. | +15

CommentIn: Hepatology. 2016 Oct;64(4):1385-6. - PMID 26970320

7

Simeprevir plus peginterferon/ribavirin for HCV genotype 1-infected treatment-naïve patients in China and South Korea

enthalten in: Journal of gastroenterology and hepatology | 2016

von Wei, L. | Han, T. | Yang, D. | +17

8

An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1)

enthalten in: PloS one | 2016

von Asselah, T. | Moreno, C. | Sarrazin, C. | +11

9

In Vitro Activity of Simeprevir against Hepatitis C Virus Genotype 1 Clinical Isolates and Its Correlation with NS3 Sequence and Site-Directed Mutants

enthalten in: Antimicrobial agents and chemotherapy | 2015

von Verbinnen, T. | Fevery, B. | Vijgen, L. | +3

10

Comparison of three quantitative HCV RNA assays in samples from HCV genotype 1- or 4-infected patients treated with the NS3/4A protease inhibitor simeprevir

enthalten in: Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology | 2015

von Fevery, B. | Susser, S. | Lenz, O. | +7